Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Department of Psychiatry, University of Vermont, Burlington, VT 05401, USA. rekast@email.com
Since deleterious effects of m-CPP, the primary catabolic metabolite of trazodone, were last reviewed 2 years ago, research data continue to accrue showing that clinically significant levels of m-CPP (a) are generated in patients using trazodone for sleep and (b) are present 24 h a day and (c) have potentially serious ill effects. This commentary argues that the documented potential for harm and multiple risks of m-CPP outweigh potential benefits of trazodone, given the development and marketing of many safer alternatives since trazodone's introduction in the 1980s.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on